Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;88(4):1804-1810.
doi: 10.1111/bcp.15097. Epub 2021 Oct 24.

Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time

Jetty A Overbeek  1 , Josephina G Kuiper  1   2 , Marina Bakker  1   3 , B J F Bart van den Bemt  4   5 , Ron M C Herings  1   6
Affiliations
Free article

Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time

Jetty A Overbeek et al. Br J Clin Pharmacol. 2022 Feb.
Free article

Abstract

Aims: The objective of this retrospective cohort study was to provide an overview of the utilization of originator and biosimilar infliximab in the Netherlands.

Methods: All infliximab dispensings were selected from the PHARMO In-patient Pharmacy Database from 2002-2018. Descriptive analyses were performed in order to characterise initiators and to describe switching patterns over time.

Results: Overall, 3840 patients with 61 274 infliximab dispensings were identified. 2496 patients initiated an originator infliximab and 777 patients initiated a biosimilar infliximab. Overall, 57% of the patients was female and mean age was 43.2 years. Both originators and biosimilars were mostly prescribed by gastroenterologists, followed by internists and rheumatologists. After market authorisation of the first biosimilar, the proportion of new patients initiating the biosimilar increased from 39% in 2015 to 91% in 2018. Out of 704 patients eligible for switching 34% switched. Among switchers, the proportion of females was 60% and mean age at index was 45.1 years. Among nonswitchers, 55% were female and mean age was 39.8 years. The median time to switch was 1.7 years and switchers were most frequently initiated on infliximab by a rheumatologist (42%), while nonswitchers were most frequently initiated by a gastroenterologist (42%).

Conclusion: The results of this large population-based cohort show an increase in biosimilar initiation in daily clinical practice. The number of switchers remains relatively low as nonmedical switch is not encouraged in the Netherlands.

Keywords: biosimilar; infliximab; market uptake; originator drug.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251-260.
    1. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355-363.
    1. European Medicines Agency. European public assessment report Remicade - infliximab. https://www.ema.europa.eu/en/medicines/human/EPAR/remicade (accessed 30 Nov 2020).
    1. Magro F, Rocha C, Vieira A, et al. The performance of Remicade-optimized quantification assays in the assessment of Flixabi levels. Therap Adv Gastroenterol. 2018;11:1-9.
    1. IUPHAR/BPS. Guide to pharmacology - infliximab. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5004 (accessed 30 Nov 2020).

LinkOut - more resources